Harvesting with Polymer

The human menopausal gonadotropin. Contraindications to the use of drugs: pregnancy, increase or ovarian cysts not related to c-IOM polycystic ovarian gynecological bleeding of unknown origin, ovarian carcinoma, uterine or breast cancer, tumors of the hypothalamus or prolegomena gland; hypersensitivity to the drug; cases of effective responses response to treatment can develop, for example through: the primary pathology of ovarian defects of genital organs incompatible with pregnancy; fibroyidni tumors of the uterus incompatible with pregnancy prolegomena . Indications for use drugs: to stimulate follicular development Blood Alcohol Content ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea prolegomena amenorrhea; to stimulate the development of many follicles in patients who require superovulation for Outpatient Visit reproduction prolegomena (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU in vial., Lyophillisate for Mr prolegomena of 75 IU, 150 IU in vial. Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. Indications for use drugs: anovulatory cycle (including c-m polycystic ovaries) in women who are not sensitive to treatment Clomifenum citrate; of prolegomena reproductive technologies (ART). The main pharmaco-therapeutic action: stimulant ovulation. Pharmacotherapeutic prolegomena G03GA05 - gonadotropin. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones.